Abstract

Synaptonemal complex protein 3 (SCP3), a member of the Cor1 family, has been implicated in cancer progression, and therapeutic resistance, as well as cancer stem cell (CSC)-like properties. Previously, we demonstrated that SCP3 promotes these aggressive phenotypes via hyperactivation of the AKT signaling pathway; however, the underlying mechanisms responsible for SCP3-induced AKT activation remain to be elucidated. In this study, we demonstrated that the EGF-EGFR axis is the primary route through which SCP3 acts to activate AKT signaling. SCP3 triggers the EGFR-AKT pathway through transcriptional activation of EGF. Notably, neutralization of secreted EGF by its specific monoclonal antibody reversed SCP3-mediated aggressive phenotypes with a concomitant reversal of EGFR-AKT activation. In an effort to elucidate the molecular mechanisms underlying SCP3-induced transcriptional activation of EGF, we identified Jun activation domain-binding protein 1 (JAB1) as a binding partner of SCP3 using a yeast two-hybrid (Y2H) assay system, and we demonstrated that SCP3 induces EGF transcription through physical interaction with JAB1. Thus, our findings establish a firm molecular link among SCP3, EGFR, and AKT by identifying the novel roles of SCP3 in transcriptional regulation. We believe that these findings hold important implications for controlling SCP3high therapeutic-refractory cancer.

Highlights

  • Introduction published maps and institutional affilSynaptonemal complex protein 3 (SCP3), a member of the Cor1 family, is a structural component of the synaptonemal complex, which mediates synapsis, pairing of homologous chromosomes during meiosis in germ cells [1]; it is mainly expressed in the testis and ovary [2]

  • We examined whether Jun activation domain-binding protein 1 (JAB1) is required for the epidermal growth factor (EGF)-epidermal growth factor receptor (EGFR) axis mediated by phosphorylation (Figure 5A), which was accompanied by decreased level of EGF protein or mRNA (Figure 5A,B)

  • Harnessing the immune system to detect and eliminate tumor cells, cancer immunoHarnessing the immune system to detect and eliminate tumor cells, cancer imtherapy has emerged as a promising cancer treatment [20]

Read more

Summary

Introduction

Synaptonemal complex protein 3 (SCP3), a member of the Cor family, is a structural component of the synaptonemal complex, which mediates synapsis, pairing of homologous chromosomes during meiosis in germ cells [1]; it is mainly expressed in the testis and ovary [2]. Previous studies provide evidence that SCP3 is important for tumor progression, metastasis, and immune resistance, as well as cancer stem cell (CSC)-like property [6,7,8]. In this regard, we demonstrated a pathway involved in SCP3-mediated multi-aggressive phenotypes of tumor cells, which is dependent on AKT signaling [6,8]. The underlying mechanisms responsible for SCP3-induced AKT activation remains to be elucidated. iations.

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.